Semarion Secures $3.8 Million in New Funding to Scale Next-Generation Cell Assay Platform

Cambridge spin-out Semarion secures $3.8 million to accelerate the adoption of its SemaCyte cell assay platform among global pharmaceutical leaders.

By: AXL Media

Published: Mar 31, 2026, 8:35 AM EDT

Source: Information for this report was sourced from Semarion.

Cambridge Spin-Out Secures Capital to Transform Drug Screening

Semarion, a biotechnology firm originating from the University of Cambridge’s Cavendish Laboratory, has successfully closed a $3.8 million funding round to advance its proprietary materials engineering and cell biology solutions. This latest injection of capital is intended to facilitate the commercial scaling and increased manufacturing throughput of the company's SemaCyte® platform. According to company officials, the technology allows adherent cell models to be managed as flexible, barcoded reagents, providing a more scalable approach to drug discovery than traditional methods. The fundraise saw participation from a diverse group of investors, including Parkwalk, The FSE Group, and Cambridge Enterprise Ventures, among others.

Strategic Focus on Pharmaceutical Adoption and Manufacturing Scale

The newly acquired funds are earmarked for a significant expansion of Semarion’s commercial operations and field application support teams. With a growing pipeline of industry interest, the company is prioritizing the broad-scale adoption of its platform among global pharmaceutical organizations. According to CEO and Co-Founder Jeroen Verheyen, the funding marks a critical step in meeting the increasing pressure on scientists to generate high-quality cell-based data while improving operational efficiency. By scaling its manufacturing capabilities, Semarion aims to translate current pilot program momentum into a wider commercial rollout across the United States and Europe.

Integration with Global Life Science Tools and Automation

Semarion has already established strategic collaborations with prominent life science tool providers to enhance the compatibility of its technology. Partnerships with organizations such as Revvity and SPT Labtech have led to the integration of SemaCyte detection into advanced imaging platforms and automated liquid handling systems. According to Karin Boettcher, Product Manager at Revvity, the use of optically barcoded cell microcarriers allows researchers to generate richer datasets without compromising on throughput. These collaborations are viewed as essential for embedding Semarion’s technology into existing industry infrastructure, allowing for more automated and information-rich cell-based workflows.